A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBC...

Full description

Bibliographic Details
Main Authors: Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
machie learning
DLBCL - diffuse large B cell lymphoma
bortezomib
R-CHOP
lymphoma
genomics
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/full

Similar Items